Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer’s disease: why it is time to abandon the approach

Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances

“…PET imaging may also be advantageous for the early evaluation of treatment response and for the discrimination of tumor recurrence, pseudoprogression and radionecrosis [12,120,121]. Although an overall good performance has been described for the assessment of recurrence using [ 18 F]FDG-PET/CT in patients with gliomas [122], a relatively high rate of false negative results has been reported in LGGs [123].…”

Aducanumab-Related Amyloid-Related Imaging Abnormalities

“…Furthermore, over the past decade, serious concerns have been raised about the role of radiolabeled compounds to detect and quantify amyloid plaques in the brain. 2 Therefore, without defendable clinical or imaging data as surrogate markers, we believe approval of Biogen's antibody is unjustified. We strongly disagree with the interpretation of the PET scans performed at baseline and following treatment with this drug.…”

Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders

“…The authors determined that, while the patterns of uptake of both FDG and florbetapir revealed evidence for AD, florbetapir does not sufficiently reflect the severity of the cognitive decline in comparison to FDG. Furthermore, multiple therapeutic trials which have used antibodies that specifically target amyloid plaques in the brain have proven to be ineffective [63,64]. These failed attempts have demonstrated the alternate methods to monitor cognitive decline during the course of the disease [65].…”

“…18 F-fluorodeoxyglucose positron emission tomography (FDG-PET/CT) and18 F-Florbetapir images of the brain in controls (NC), mild cognitive impairment subjects (MCI), and Alzheimer's disease (AD) patients, demonstrating the superiority of FDG-PET/CT (reproduced with permission from Alavi et al[64])…”